HK1038507A1 - Influenza virus vaccine composition - Google Patents

Influenza virus vaccine composition

Info

Publication number
HK1038507A1
HK1038507A1 HK02100022A HK02100022A HK1038507A1 HK 1038507 A1 HK1038507 A1 HK 1038507A1 HK 02100022 A HK02100022 A HK 02100022A HK 02100022 A HK02100022 A HK 02100022A HK 1038507 A1 HK1038507 A1 HK 1038507A1
Authority
HK
Hong Kong
Prior art keywords
influenza virus
virus vaccine
vaccine composition
mug
virus antigen
Prior art date
Application number
HK02100022A
Other languages
English (en)
Inventor
Otfried Kistner
Noel Barrett
Wolfgang Mundt
Friedrich Dorner
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3515932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1038507(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Publication of HK1038507A1 publication Critical patent/HK1038507A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK02100022A 1998-09-15 2002-01-03 Influenza virus vaccine composition HK1038507A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0155598A AT408615B (de) 1998-09-15 1998-09-15 Neue influenzavirus-impfstoffzusammensetzung
PCT/AT1999/000223 WO2000015251A2 (fr) 1998-09-15 1999-09-14 Nouvelle composition de vaccin contre le virus grippal

Publications (1)

Publication Number Publication Date
HK1038507A1 true HK1038507A1 (en) 2002-03-22

Family

ID=3515932

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02100022A HK1038507A1 (en) 1998-09-15 2002-01-03 Influenza virus vaccine composition

Country Status (12)

Country Link
US (1) US6372223B1 (fr)
EP (1) EP1113816B1 (fr)
JP (1) JP2003523310A (fr)
AT (2) AT408615B (fr)
AU (1) AU763210B2 (fr)
DE (1) DE59913046D1 (fr)
DK (1) DK1113816T3 (fr)
ES (1) ES2257072T3 (fr)
HK (1) HK1038507A1 (fr)
HU (1) HUP0103908A3 (fr)
NO (1) NO20011282L (fr)
WO (1) WO2000015251A2 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
ES2327103T3 (es) * 2000-09-25 2009-10-26 Polymun Scientific Immunbiologische Forschung Gmbh Vacuna viva de influenzavirus y procedimiento de fabricacion.
EP1416986A4 (fr) * 2001-06-29 2005-12-14 Becton Dickinson Co Distribution intradermique de vaccins et d'agents therapeutiques geniques via une microcannule
IL145926A0 (en) * 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
US20070053923A1 (en) * 2003-01-30 2007-03-08 Ki-Seok Park Dna vaccine composition with enhanced immunogenicity
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
JP4558652B2 (ja) 2003-06-20 2010-10-06 マイクロビクス・バイオシステムズ・インコーポレイテツド ウイルス生産の改善
US20050281832A1 (en) * 2003-12-05 2005-12-22 Campbell Robert L Methods of enhancing immune response in the intradermal compartment and compounds useful thereof
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
BRPI0509493A (pt) * 2004-04-01 2007-09-11 Alza Corp aparelho e método para a liberação transdérmica de vacina da influenza
EP1739167B1 (fr) * 2004-04-19 2015-08-12 DENKA SEIKEN Co., Ltd. Méthode de production de virus
DE602005024827D1 (de) 2004-09-09 2010-12-30 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
JP2008519042A (ja) 2004-11-03 2008-06-05 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド インフルエンザワクチン接種
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
AU2006226458B2 (en) * 2005-03-23 2012-08-30 Glaxosmithkline Biologicals S.A. Novel composition
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628152C (fr) * 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire
CN102727885A (zh) 2005-11-04 2012-10-17 诺华疫苗和诊断有限公司 包含颗粒佐剂和免疫增强剂组合的流感疫苗
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
EP1957104B1 (fr) * 2005-11-04 2012-03-21 Novartis Vaccines and Diagnostics S.r.l. Vaccins de la grippe adsorbés extemporanément sur des adjuvants à base d aluminium
GB0522601D0 (en) * 2005-11-04 2005-12-14 Chiron Srl Adjuvanted influenza vaccines and kits
KR20110110853A (ko) 2006-01-27 2011-10-07 노파르티스 파르마 아게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
CA2646349A1 (fr) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Stockage de vaccins antigrippaux sans refrigeration
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
KR101696727B1 (ko) 2006-07-17 2017-01-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 인플루엔자 백신
EP3456348A1 (fr) 2006-09-11 2019-03-20 Seqirus UK Limited Fabrication de vaccins contre le virus de la grippe sans utiliser d' ufs
CA2671629C (fr) 2006-12-06 2017-08-15 Novartis Ag Vaccins comprenant un antigene issu de quatre souches du virus grippal
EP2114991A1 (fr) * 2007-02-07 2009-11-11 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Antigenes recombinants du cytomegalovirus humain (hcmv)
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
CA2692200A1 (fr) 2007-06-27 2008-12-31 Novartis Ag Vaccins antigrippaux a faible teneur en additifs
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009081172A1 (fr) 2007-12-24 2009-07-02 Novartis Ag Dosages pour vaccins adsorbés contre la grippe
JP5689796B2 (ja) * 2008-08-01 2015-03-25 ガマ ワクチンズ ピーティワイ リミテッド インフルエンザワクチン
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
WO2011005772A1 (fr) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Procédés pour préparer des vésicules et formulations produites à partir de ces procédés
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
MX2012004067A (es) 2009-10-09 2012-08-03 Cbio Ltd Variantes de la chaperonina 10.
US9107875B2 (en) 2009-11-18 2015-08-18 Auburn University Low antigen-dose immunization for maximizing T-helper cell 1 (Th1) immunity against a pathogen
WO2012006367A2 (fr) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions et méthodes pour traiter la grippe
WO2012032482A1 (fr) 2010-09-07 2012-03-15 Novartis Ag Tests génériques pour la détection de réovirus de mammifères
FR2966044B1 (fr) 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
WO2012097346A1 (fr) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions et méthodes de traitement d'infections virales
EP2667891B1 (fr) 2011-01-27 2021-10-06 Gamma Vaccines Pty Limited Vaccins associés
WO2013072768A2 (fr) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Dérivés synthétiques de mpl et ses utilisations
EP2802353A4 (fr) 2012-01-12 2015-12-02 Variation Biotechnologies Inc Compositions et méthodes de traitement d'infections virales
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
KR102055176B1 (ko) 2012-03-23 2019-12-12 피트니 파마슈티컬스 피티와이 리미티드 암 치료용 키나제 저해제
CA2875683A1 (fr) 2012-06-05 2013-12-12 The Australian National University Vaccination avec des antagonistes de l'interleukine-4
ES2627099T3 (es) 2012-08-06 2017-07-26 Pitney Pharmaceuticals Pty Limited Compuestos para el tratamiento de enfermedades relacionadas con la vía de mTOR
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
KR102255753B1 (ko) 2012-12-17 2021-05-26 뉴사우스 이노베이션즈 피티와이 리미티드 뮤신 관련 질환의 치료
WO2014100857A1 (fr) 2012-12-24 2014-07-03 Cell Ideas Pty Ltd Vaccins pour traiter le cancer et compositions pour améliorer l'efficacité des vaccins
US10364277B2 (en) 2013-07-01 2019-07-30 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
US20150166255A1 (en) * 2013-12-12 2015-06-18 ASCLEMED USA, INC. dba EnovaChem Manufacturing Vitamin b-12 injection kit
EP3134118B1 (fr) 2014-04-18 2020-01-22 Auburn University Formulations de vaccin particulaire pour induire l'immunité innée et acquise
US10293044B2 (en) 2014-04-18 2019-05-21 Auburn University Particulate formulations for improving feed conversion rate in a subject
CA2980616A1 (fr) 2015-03-26 2016-09-29 Gpn Vaccines Pty Ltd Vaccin streptococcique
WO2018176103A1 (fr) 2017-03-30 2018-10-04 The University Of Queensland Molécules chimériques et utilisations associées

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE168271T1 (de) * 1992-05-23 1998-08-15 Smithkline Beecham Biolog Kombinierte impfstoffe, die hepatitis b oberfläche antigen und andere antigenen enthalten
EP2290053A1 (fr) * 1994-11-10 2011-03-02 Baxter Healthcare S.A. Procédé pour la production du virus de la grippe dans un milieu de culture céllulaire sans protéines
FR2754715B1 (fr) * 1996-10-18 1998-11-13 Seppic Sa Adjuvant, notamment sous forme d'une emulsion contenant un cation metallique trivalent et composition vaccinale le comprenant
US5795582A (en) 1996-02-07 1998-08-18 Novavax, Inc. Adjuvant properties of poly (amidoamine) dendrimers

Also Published As

Publication number Publication date
DK1113816T3 (da) 2006-04-03
NO20011282D0 (no) 2001-03-14
HUP0103908A2 (hu) 2002-02-28
ES2257072T3 (es) 2006-07-16
EP1113816A2 (fr) 2001-07-11
ATA155598A (de) 2001-06-15
NO20011282L (no) 2001-05-14
US6372223B1 (en) 2002-04-16
WO2000015251A2 (fr) 2000-03-23
WO2000015251A3 (fr) 2000-08-24
ATE315404T1 (de) 2006-02-15
JP2003523310A (ja) 2003-08-05
AU5720099A (en) 2000-04-03
DE59913046D1 (de) 2006-04-06
EP1113816B1 (fr) 2006-01-11
AU763210B2 (en) 2003-07-17
HUP0103908A3 (en) 2003-10-28
AT408615B (de) 2002-01-25

Similar Documents

Publication Publication Date Title
HK1038507A1 (en) Influenza virus vaccine composition
UA85536C2 (en) Viral antigens
HK1048434A1 (en) Influenza vaccine
MY133780A (en) Vaccine composition
HK1142093A1 (en) Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
AU2001262345A1 (en) Antigenic composition comprising a polycationic peptide and inosine and cytosine
GB9817052D0 (en) Vaccine
EP0914134A4 (fr) Proprietes adjuvantes de dendrimeres de polyamidoamines
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
BG104511A (en) Spheroids, preparation method and pharmaceutical compositions
AU5457596A (en) Adjuvants for viral vaccines
CA2372960A1 (fr) Compositions et procedes immunogenes anti-vih
YU8004A (sh) Vakcina protiv bolesti zapadnog nila
YU24004A (sh) Interleukin-12 kao adjuvant veterinarske vakcine
GB2386072A (en) Novel vaccine
AU5457496A (en) Adjuvants for viral vaccines
EP1395283A4 (fr) Protection heterologue induite par immunisation avec un vaccin d'invaplex
UA42741C2 (uk) Пептид маститної вакцини (варіанти), пептид складного антигенного представлення (варіанти), фармацевтична композиція (варіанти)
WO2004033483A3 (fr) Systeme liposomal et son procede d'utilisation
WO2002032455A3 (fr) Vaccin
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
CA2176929A1 (fr) Vaccin contre les oreillons contenant une souche virale jeryl-lynn
DK1401492T3 (da) LTB4 som vaccineadjuvans
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus
WO2002060469A1 (fr) Agents anticancereux

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120914